CURR News and Press, Cure Pharmaceutical Holding Corp From 07/28/22

CURE Pharmaceutical ( OTCQB:CURR ) sold a portion of its platform technology intellectual property and related assets for $20M in total consideration. Company used a portion of the cash proceeds to pay down certain debt obligations and the balance will be used to grow its...

OXNARD, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that it has sold a portion of its platform technology intellectual property and related assets for $20 milli...

CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease (GVHD) CCHMC to Seek Formulary approval f...

LOS ANGELES, April 14, 2022 (GLOBE NEWSWIRE) -- Sera Labs , a wholly subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced its Seratopical Revolution skincare line will be sold at select Walmart Stores, as well as CVS, and Bed Bath & Beyond sto...

OXNARD, Calif. and LAS VEGAS, March 03, 2022 (GLOBE NEWSWIRE) -- Cure Pharmaceutical (OTC: CURR) a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, and Milagro Pharmaceuticals, which seeks first mover advantage in target heath &...

The Sera Labs, a wholly owned subsidiary of CURE Pharmaceutical (OTCQB:CURR) announced its global expansion into Canada by engaging Northern Response International for the exclusive distribution of the entire plant-based, clean Seratopical Revolution skin care line. Northern Response Internat...

LOS ANGELES and TORONTO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Sera Labs, a wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR) today announced its global expansion into Canada by engaging Northern Response International for the exclusive distribution of the entire pla...

CURE Pharmaceutical (OTCQB:CURR) has received an issue notification from the USPTO stating that U.S. Patent No. 11,179,331 is set to issue on November 23, 2021. The ’331 patent, entitled “Oral Soluble Film Containing Sildenafil Citrate,” covers the product CUREfilm Blue, ...

CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company focused on pharmaceutical and health & wellness products, announced today that it received an issue notification from the U.S. Patent Office (USPT...

CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced results for the quarter ended June 30, 2021, including the following highlights: Revenue of $2.1 million reflected an increase of nearly 700% from a year ago Gross profit rose 676% to $1.31 million compar...